Tag: loan agreement

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

Allschwil, Switzerland – June 26, 2026
Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today confirmed the successful closing of its previously announced senior secured term loan agreement of up to CHF 250 million with investment funds managed by Pharmakon Advisors, LP.

AB “Ignitis grupė” (hereinafter – the Group) informs that on 16 June 2026 a EUR 150 million loan agreement (hereinafter – the Loan) was concluded between the Group and European Investment Bank.

AB “Ignitis grupė” (hereinafter – the Group) informs that on 16 June 2026 a EUR 150 million loan agreement (hereinafter – the Loan) was concluded between the Group and European Investment Bank.

AS PRFoods (registry code 11560713) hereby notifies that its subsidiary Saaremere Kala AS (registry code  11310040, hereinafter "Seller") has completed previously announced transaction (as disclosed in a stock exchange announcement published by AS PRFoods on 23 April 2026 (https://view.news.eu.nasdaq.com/view?id=1436682&lang=en), whereby 100% shareholding in Saare Kala Tootmine OÜ (registry code 10377013, hereinafter "SKT") was sold and claims arising from shareholder loans and an inventory loan provided to SKT were transferred to the Latvian company Brīvais Vilnis A/S (Latvian registry code: 40003056186, hereinafter "Buyer"). The general meeting of shareholders of AS PRFoods approved the transaction by their relevant resolution published on 18 May 2026 (https://view.news.eu.nasdaq.com/view?id=1442522&lang=en). In accordance with the terms of the transaction, the vendor note agreement concluded between the Seller and the Buyer and setting out the terms of the payment by the Buyer to the Seller of the amount equal to the outstanding purchase price for the share of SKT and of the transfer price for the inventory loans has entered into force upon completion of the transaction.

TORTOLA, British Virgin Islands, June 05, 2026 (GLOBE NEWSWIRE) -- Orca Energy Group Inc. (“Orca” or the “Company” and includes its subsidiaries and affiliates) (TSX-V: ORC.A, ORC.B) today announces that it has filed its condensed consolidated interim (unaudited) financial statements and management’s discussion and analysis for the three month period ended March 31, 2026 (“Q1 2026”) with the Canadian securities regulatory authorities. All amounts are in United States dollars (“$”) unless otherwise stated.

MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032 (the “Convertible Notes”). The aggregate principal amount of the offering was increased from the previously announced offering size of $400,000,000.

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -